Latest Headlines

Latest Headlines

Are specialty pharma CEOs worth their salt?

Specialty drugmakers often find their treatments scrutinized, with critics wondering if they're worth their sometimes high price tags. But what about their CEOs?

Bayer's startup accelerator funds 5 device, healthcare app companies

Fresh off the sales of its interventional device unit to Boston Scientific, Bayer Healthcare is showing renewed interest in med tech via its startup accelerator.

Could a pair of offerings be the first signs of animal health IPO momentum?

A pair of public offerings recently announced could be signs the animal health sector is finding an appetite for IPOs.

Med tech IPOs for NeuroSigma, ReWalk ready for fall

Epilepsy devicemaker NeuroSigma filed to raise up to $50 million in an IPO, while ReWalk--whose mobile exoskeletons were recently approved by the FDA--set IPO terms to raise $50 million.

Mobile medical app provider reels in $25M to expand innovative monitoring system

Mobile medical app provider AirStrip reeled in $25 million in strategic capital to beef up its product offerings and develop its innovative health monitoring system for smartphones.

China's Luye Pharma founder soars into pharma's billionaire echelon

China's pharma corruption crackdown hasn't helped multinationals' top lines, which only recently began returning to normal after taking a hit last fall. But it may be opening up an opportunity for domestic drugmakers and their owners--like new Billionaire Club member Liu Dian Bo--to make a splash.

Endo reported to be selling its AMS medical device unit

Endo Health Solutions is shopping its medical device unit American Medical Systems. The Minnetonka, MN-based company was recently in the news for settling many of its vaginal mesh-related lawsuits, and has caught the attention of private-equity firms and other health care companies.

Parexel: Biotech's boom pays dividends for CROs

Like most CROs, Parexel International relies on Big Pharma for most of its service revenue. But the recent explosion in biotech IPOs and venture capital deals has put a lot of money in the hands of small drugmakers, and that's changing the approach for the industry's largest contractors, a company exec said.

China's Skystar Bio-Pharmaceutical sees revenue grow 25%

Some animal health companies see China as key for expansion. But the large market has its own domestic players, including Skystar Bio-Pharmaceutical. And it is seeing growth itself.

Claret Medical ropes in $18M to develop cerebral protection system for TAVR procedures

Claret Medical roped in $18 million in Series B financing to support development of its cerebral protection system for transcatheter aortic valve replacement.